Stating the obvious here for all those tracking or invested in Natco Pharma
Price has given an Inverse Head & Shoulders pattern completion (on multiple time frames), whether or not retest has been done I leave it to ones own judgement… fundamentally, profits have never been greater, operating margins at an enviable 40% +, expecting contribution from grevlimid to continue in FY24-25 as well as the share price to break through the previous ATH by the time we are face to face with the Q4 results which willmost likely be around the last week of May… the market prices the share at a modest 14PE…the kothur plant usfda issue remains a thorn in the bullish thesis…
the neck of the h&s would be the logical stop loss area
Subscribe To Our Free Newsletter |